Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · market

Telix buys ITM in bid to create a 'radiopharmaceutical powerhouse'

21 September 2026 · By · Wire by Fusion42

Published

21 September 2026

Topic

market

◆ Sectors

BiotechMedtech

◆ Geography

AustraliaGermany

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 21 September 2026 · Fusion42 review

Telix has acquired ITM in a $1.65 billion deal to combine their radiopharmaceutical pipelines and manufacturing networks, aiming to dominate the radiopharmaceutical industry.

This Wire brief sits within Fusion42's coverage of Biotech and Medtech.

◆ ◆ The Wire takeaway

The combined strength of Telix and ITM reshapes the radiopharmaceutical market, forcing biotech founders to reassess partnerships and competitive positioning with a dominant new player emerging.

◆ Coverage

1 source · 21 Sep 2026

◆ Related on Wire

◆ Topics

BiotechMedtechm-aradiopharmaceuticalsbiotechmanufacturingpipelines